Current treatment of hypertension in patients with coronary artery disease recommended by different guidelines

Bibliography

• Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. the JNC 7 report. JAMA 2003;289:2560-72
   PubMed Web of Science ®Google Scholar
• Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease. A scientific statement from the American heart association council for high blood pressure research and the councils on clinical cardiology and epidemiology and prevention. Circulation 2007;115:2761-88
   PubMed Web of Science ®Google Scholar
• Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American college of cardiology foundation task force on clinical expert consensus documents. J Am Coll Cardiol 2011;57:2037-114
   PubMed Web of Science ®Google Scholar
• Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013 34:2159-219
   Google Scholar
• Banach M, Bromfield S, Howard G, et al. Association of systolic blood pressure levels with cardiovascular events and all-cause mortality among older adults taking antihypertensive medication. Int J Cardiol 2014;176:219-26
   PubMed Web of Science ®Google Scholar
• Bangalore S, Gong Y, Cooper-DeHoff RM, et al. 2014 Eighth Joint National Committee Panel recommendation for blood pressure targets revisited: results from the INVEST study. J Am Coll Cardiol 2014;64:784-93
   PubMed Web of Science ®Google Scholar
• Hackam DG, Quinn RR, Ravani P, et al. The 2013 Canadian hypertension education program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 2013;29:528-42
   PubMed Web of Science ®Google Scholar
• Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community. a statement by the American society of hypertension and the international society of hypertension. J Clin Hypertens (Greenwich) 2014;16:14-26
   PubMed Web of Science ®Google Scholar
• Rosendorff C, Lackland DT, Allison M, et al. AHA/ACC/ASH scientific statement. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. J Am Coll Cardiol 2015;65:1998-2038
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics-2009 update: a report from the American heart association statistics committee and stroke statistics subcommittee. Circulation 2009;119:e21-e181
   PubMed Web of Science ®Google Scholar
• Smith SCJr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease:2011 update. a guideline from the American heart association and American college of cardiology foundation. endorsed by the World heart federation and the preventive cardiovascular nurses association. J Am Coll Cardiol 2011;58:2432-46
   PubMed Web of Science ®Google Scholar
• Joseph AM, Norman SM, Ferry LH, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med 1996;335:1792-8
   PubMed Web of Science ®Google Scholar
• Eisenberg MJ, Grandi SM, Gervais A, et al. Bupropion for smoking cessation in patients hospitalized with acute myocardial infarction. a randomized, placebo-controlled trial. J Am Coll Cardiol 2013;61:524-32
   PubMed Web of Science ®Google Scholar
• Rigotti NA, Pipe AL, Benowitz NL, et al. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease. a randomized trial. Circulation 2010;121:221-9
   PubMed Web of Science ®Google Scholar
• Cocco G, Pandolfi S. Physical exercise with weight reduction lowers blood pressure and improves abnormal left ventricular relaxation in pharmacologically treated hypertensive patients. J Clin Hypertens 2011;13:23-9
   PubMed Web of Science ®Google Scholar
• Cocco G, Chu D. Weight reduction reduces NT-proBNP levels in patients with chronic diastolic heart failure. Arch Med Sci 2007;2:112-16
   Google Scholar
• Gasparyan AY, Ayvazyan L, Cocco G, et al. Adverse cardiovascular effects of antirheumatic drugs: implications for clinical practice and research. Curr Pharm Des 2012;18:1543-55
   PubMed Web of Science ®Google Scholar
• Miettinen TA, Pyorala K, Olsson AG, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris. findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 1997;96:4211-18
   PubMed Web of Science ®Google Scholar
• Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the cholesterol and recurrent events (CARE) Trial. Ann Intern Med 1998;129:681-9
   PubMed Web of Science ®Google Scholar
• The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
   PubMed Web of Science ®Google Scholar
• Aronow WS, Ahn C. Incidence of new coronary events in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol ≥125 mg/dL treated with statins versus no lipid-lowering drug. Am J Cardiol 2002;89:67-9
   PubMed Web of Science ®Google Scholar
• Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol 2014 63:2889-934
   Google Scholar
• Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2387-97
   PubMed Web of Science ®Google Scholar
• Garratt KN, Brady PA, Hassinger NL, et al. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999;33:119-24
   PubMed Web of Science ®Google Scholar
• O’Keefe JH, Blackstone EH, Sergeant P, McCallister BD. The optimal mode of coronary revascularization for diabetics. Eur Heart J 1998;19:1696-703
   PubMed Web of Science ®Google Scholar
• Aronow WS, Ahn C. Incidence of new coronary events in older persons with diabetes mellitus and prior myocardial infarction treated with sulfonylureas, insulin, metformin, and diet alone. Am J Cardiol 2001;88:556-7
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Position statement. Standards of Medical Care in Diabetes-2013. Diabetes Care 2013;36(Suppl 1):S11-66
   PubMed Web of Science ®Google Scholar
• Qaseem A, Humphrey LL, Sweet DE, et al. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American college of physicians. Ann Intern Med 2012;156:218-31
   PubMed Web of Science ®Google Scholar
• Williams MA, Maresh CM, Aronow WS, et al. The value of early out-patient cardiac exercise programmes for the elderly in comparison with other selected age groups. Eur Heart J 1984;5(Suppl E):113-15
   PubMed Web of Science ®Google Scholar
• Aronow WS. Exercise therapy for older persons with cardiovascular disease. Am J Geriatr Cardiol 2001;10:245-52
   PubMedGoogle Scholar
• Law MR, Morris JK, Wald NJ. Use of BP lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665
   PubMed Web of Science ®Google Scholar
• Aronow WS, Frishman WH. Angina pectoris in the elderly. In: Aronow WS, Fleg J, Rich MW, editor. Tresch and Aronow’s cardiovascular disease in the elderly. 5th edition. CRC press; Boca Raton: London: New York: 2013. p. 215-37
   Google Scholar
• Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA 1993;270:1589-95
   PubMed Web of Science ®Google Scholar
• Hansteen V. Beta blockade after myocardial infarction: The Norwegian Propranolol Study in high-risk patients. Circulation 1983;67(Suppl I):I57-60
   PubMedGoogle Scholar
• Hjalmarson A, Elmfeldt D, Herlitz J, et al. Effect on mortality of metoprolol in acute myocardial infarction. Lancet 1981;2:823-7
   PubMed Web of Science ®Google Scholar
• Gundersen T, Abrahamsen AM, Kjekshus J, et al. Timolol-related reduction in mortality and reinfarction in patients ages 65-75 years surviving acute myocardial infarction. Circulation 1982;66:1179-84
   PubMed Web of Science ®Google Scholar
• Pedersen TR for the Norwegian Multicentre Study Group. Six-year follow-up of the Norwegian multicentre study on timolol after acute myocardial infarction. N Engl J Med 1985;313:1055-8
   PubMed Web of Science ®Google Scholar
• Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. JAMA 1982;247:1707-14
   PubMed Web of Science ®Google Scholar
• The CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385-90
   PubMed Web of Science ®Google Scholar
• Park KC, Forman DE, Wei JY. Utility of beta-blockade treatment for older postinfarction patients. J Am Geriatr Soc 1995;43:751-5
   PubMed Web of Science ®Google Scholar
• Cocco G, Chu D. The anti-ischemic effect of metoprolol in patients with chronic angina pectoris is gender-specific. Cardiology 2006;106:147-53
   PubMed Web of Science ®Google Scholar
• Chadda K, Goldstein S, Byington R, Curb JD. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 1986;73:503-10
   PubMed Web of Science ®Google Scholar
• The Beta-Blocker Pooling Project Research Group. The Beta-Blocker Pooling Project (BBPP): subgroup findings from randomised trials in post-infarction patients. Eur Heart J 1988;9:8-16
   Web of Science ®Google Scholar
• Lichstein E, Hager WD, Gregory JJ, et al. Relation between beta-adrenergic blocker use, various correlates of left ventricular function and the chance of developing congestive heart failure. J Am Coll Cardiol 1990;16:1327-32
   PubMed Web of Science ®Google Scholar
• MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999;353:2001-7
   PubMed Web of Science ®Google Scholar
• CIBIS-II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13
   PubMed Web of Science ®Google Scholar
• Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in chronic heart failure. N Engl J Med 2001;344:651-8
   Web of Science ®Google Scholar
• Flather MD, Shibata MC, Coats AJS, et al. Randomized trial to determine the effect of nevibolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215-25
   PubMed Web of Science ®Google Scholar
• Aronow WS, Ahn C, Kronzon I. Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction ≥40% treated with diuretics plus angiotensin-converting-enzyme inhibitors. Am J Cardiol 1997;80:207-9
   PubMed Web of Science ®Google Scholar
• Aronow WS, Ahn C, Kronzon I. Effect of beta blockers alone, of angiotensin-converting enzyme inhibitors alone, and of beta blockers plus angiotensin-converting enzyme inhibitors on new coronary events and on congestive heart failure in older persons with healed myocardial infarcts and asymptomatic left ventricular systolic dysfunction. Am J Cardiol 2001;88:1298-300
   PubMed Web of Science ®Google Scholar
• Soumerai SB, McLaughlin TJ, Spiegelman D, et al. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA 1997;277:115-21
   PubMed Web of Science ®Google Scholar
• Aronow WS, Ahn C, Mercando AD, et al. Effect of propranolol versus no antiarrhythmic drug on sudden cardiac death, total cardiac death, and total death in patients ≥62 years of age with heart disease, complex ventricular arrhythmias, and left ventricular ejection fraction ≥40%. Am J Cardiol 1994;74:267-70
   PubMed Web of Science ®Google Scholar
• Kennedy HL, Brooks MM, Barker AH, et al. Beta-blocker therapy in the cardiac arrhythmia suppression trial. Am J Cardiol 1994;74:674-80
   PubMed Web of Science ®Google Scholar
• Aronow WS, Ahn C, Mercando AD, et al. Decrease of mortality by propranolol in patients with heart disease and complex ventricular arrhythmias is more an anti-ischemic than an antiarrhythmic effect. Am J Cardiol 1994;74:613-15
   PubMed Web of Science ®Google Scholar
• Aronow WS, Ahn C, Mercando AD, Epstein S. Effect of propranolol on circadian variation of ventricular arrhythmias in elderly patients with heart disease and complex ventricular arrhythmias. Am J Cardiol 1995;75:514-16
   PubMed Web of Science ®Google Scholar
• Aronow WS, Ahn C, Mercando AD, Epstein S. Effect of propranolol on circadian variation of myocardial ischemia in elderly patients with heart disease and complex ventricular arrhythmias. Am J Cardiol 1995;75:837-9
   PubMed Web of Science ®Google Scholar
• Aronow WS, Ahn C, Mercando AD, Epstein S. Circadian variation of sudden cardiac death or fatal myocardial infarction is abolished by propranolol in patients with heart disease and complex ventricular arrhythmias. Am J Cardiol 1994;74:819-21
   PubMed Web of Science ®Google Scholar
• Yusuf S, Wittes J, Probstfield J. Evaluating effects of treatment subgroups of patients within a clinical trial: the case of non-Q-wave myocardial infarction and beta blockers. Am J Cardiol 1990;60:220-2
   Web of Science ®Google Scholar
• Aronow WS. Might losartan reduce sudden cardiac death in diabetic patients with hypertension? Lancet 2003;362:591-2
   PubMed Web of Science ®Google Scholar
• Carlberg B, Samuelson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004;364:1684-9
   PubMed Web of Science ®Google Scholar
• Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against losartan. Lancet 2002;359:995-1003
   PubMed Web of Science ®Google Scholar
• Aronow WS. Current role of beta blockers in the treatment of hypertension. Expert Opin Pharmacotherap 2010;11:2599-607
   PubMed Web of Science ®Google Scholar
• HOPE (Heart outcomes prevention evaluation) study investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:669-77
   PubMed Web of Science ®Google Scholar
• The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8
   PubMed Web of Science ®Google Scholar
• Ambrosioni E, Borghi C, Magnani B; for the Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995;332:80-5
   PubMed Web of Science ®Google Scholar
• Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;333:1670-6
   PubMed Web of Science ®Google Scholar
• The European trial on reduction of cardiac events with perindopril in stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8
   PubMed Web of Science ®Google Scholar
• ONTARGET Investigators. Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59
   PubMed Web of Science ®Google Scholar
• Kasanuki H, Hagiwara N, Hosoda S, et al. Angiotensin II receptor blockade-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart institute of Japan Candesartan Randomized Trial for Evaluation in Coronary artery disease (HIJ-CREATE). Eur Heart J 2009;30:1203-12
   PubMed Web of Science ®Google Scholar
• Dickstein K, Kjekshus J; OPTIMAAL steering committee of the OPTIMAAL study group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomized trial. optimal trial in myocardial infarction with angiotensin II antagonist losartan. Lancet 2002;360:752-60
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906
   PubMed Web of Science ®Google Scholar
• Jhund PS, McMurray JJ, Chaturvedi N, et al. Mortality following a cardiovascular or renal event in patients with type 2 diabetes in the ALTITUDE trial. Eur Heart J 2015. [Epub ahead of print]
   Google Scholar
• Danahy DT, Aronow WS. Hemodynamics and antianginal effects of high dose oral isorbide dinitrate after chronic use. Circulation 1977;56:205-12
   PubMed Web of Science ®Google Scholar
• Cocco G, Jerie P, Iselin HU. Use of nitrates in ischemic heart disease. Expert Opin Pharmacother 2015
   Web of Science ®Google Scholar
• Parker JO, Farrell B, Lahey KA, Moe G. Effect of interval between doses on the development of tolerance to isosorbide dinitrate. N Engl J Med 1987;316:1440-4
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Hagiwara N, Kasanuki H, et al. Long-term nitrate use in acute myocardial infarction (the Heart Institute of Japan, department of cardiology nitrate evaluation program). Cardiovasc Drugs Ther 2008;22:177-84
   PubMed Web of Science ®Google Scholar
• Yamaguchi J, Hagiwara N, Ogawa H, et al. Effect of amlodipine + candesartan on cardiovascular events in hypertensive patients with coronary artery disease (from the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE) Study. Am J Cardiol 2010;106:819-24
   PubMed Web of Science ®Google Scholar
• Khera S, Kolte D, Aronow WS. Use of ranolazine in patients with stable angina pectoris. Cardiology 2014;128:251-8
   PubMed Web of Science ®Google Scholar
• Cocco G. Management of myocardial ischemia. is ranolazine needed? for all or some patients with myocardial ischemia. Expert Opin Pharmacother 2012;13:2429-32
   PubMed Web of Science ®Google Scholar
• The IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact of Nicorandil in Angina (IONA) randomised trial. Lancet 2002;359:1269-75
   PubMed Web of Science ®Google Scholar
• Fox K, Ford I, Steg G, et al. Ivabradine for patients with stable coronary artery disease and left ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:807-16
   PubMed Web of Science ®Google Scholar
• Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21
   PubMed Web of Science ®Google Scholar
• Aronow WS. Hypertension guidelines. Hypertension 2011;58:347-8
   PubMed Web of Science ®Google Scholar
• Bangalore S, Qin J, Sloan S, et al. What is the optimal blood pressure in patients after acute coronary syndromes? Relationship of blood pressure and cardiovascular events in the Pravastatin or Atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction (PROVE IT-TIMI) 22 trial. Circulation 2010;122:2142-51
   PubMed Web of Science ®Google Scholar
• Banach M, Aronow WS. Blood pressure J-curve. Curr Hypertens Rep 2012;14:556-66
   PubMed Web of Science ®Google Scholar
• Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010;304:61-8
   PubMed Web of Science ®Google Scholar
• Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Eng J Med 2008;358:1887-98
   PubMed Web of Science ®Google Scholar
• Aronow WS, Ahn C. Incidence of new coronary events in older persons with prior myocardial infarction and systemic hypertension treated with beta blockers, angiotensin-converting enzyme inhibitors, diuretics, calcium antagonists, and alpha blockers. Am J Cardiol 2002;89:1207-9
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guidelines for the management of heart failure: executive summary. a report of the American college of cardiology foundation/American heart association task force on practice guidelines. developed in collaboration with the American college of chest physicians, heart rhythm society, and international society for heart and lung transplantation. endorsed by the American association of cardiovascular and pulmonary rehabilitation. J Am Coll Cardiol 2013;62:1495-539
   Web of Science ®Google Scholar
• Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55
   PubMed Web of Science ®Google Scholar
• Garg R, Yusuf S; for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995;273:1450-6
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906
   PubMed Web of Science ®Google Scholar
• Granger CB, McMurray JJV, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772-6
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17
   PubMed Web of Science ®Google Scholar